batimastat

batimastat

A non-cytotoxic inhibitor of matrix metalloproteinase, which inhibits matrix digestion, cell migration and smooth muscle cell migration without interfering with re-endothelialisation. It was first formulated as an anti-cancer drug and later studied for preventing in-stent restenosis, as it selectively targets migrating cells. The BRILLIANT-EU trial concluded that batimastat is no more effective than standard coated stents.

batimastat

Oncology An anticancer angiogenesis inhibitor of matrix metalloproteinase
References in periodicals archive ?
13) showed that HER-2/neu ECD shedding was inhibited by broad-spectrum MMP inhibitors such as EDTA, TAPI-2, and Batimastat and confirmed the data from Christianson et al.
E21R, in Phase II development for acute myeloid leukaemia in collaboration with BresaGen Ltd; - the Batimastat BiodivYsio(R) stent, in pivotal patient trials in Europe, in collaboration with Biocompatibles International plc; - BB-10153, a novel, thrombolytic that is planned to enter Phase II studies in Q1 2002.
the Batimastat BiodivYsio stent, in pivotal patient trials in Europe, in collaboration with Biocompatibles International plc;
Registry study for the Batimastat BiodivYsio(R) stent in restenosis
In numerical terms this is the same as last year with two product failures, E21R and the Batimastat BiodivYsio(R) stent, being balanced by the addition of BB-83698 and MG-98.
Batimastat BiodivYsio(TM) stent -Collaboration with Biocompatibles International plc; UK, targeted at vascular restenosis.
Antibiotic Program -- BB-83698 to start Phase I by October 2002 -- Nine presentations at 41st ICAAC (December 2001); eight presentations accepted for 42nd ICAAC (September 2002) -- Biodefense research agreement with UK Government's Defense Science and Technology Laboratory -- Batimastat BiodivYsio(R) stent -- Development suspended -- Final stage of restructuring completed with the sale of non-core assets to OSI Pharmaceuticals, Inc.
Six-month angiographic and clinical follow-up on an initial group of patients from BRILLIANT I has indicated that the Batimastat BiodivYsio(R) stent did not show the benefit that was evident in the pre-clinical studies.
Patient studies initiated with three products -- Phase I for BB-10901 in small cell lung cancer -- Phase II for E21R in acute myeloid leukemia -- Registry study for the Batimastat BiodivYsio(R) stent in restenosis -- Manufacturing under way for a phase II study of the novel thrombolytic, BB-10153 -- Restructuring completed, non-core assets sold -- Loss for the half year of (pound)8.
Batimastat BiodivYsio stent, the drug-coated stent being